Company Update (NYSE:LLY): Lilly’s CYRAMZA® (ramucirumab) in Combination with Paclitaxel Granted FDA Approval for Advanced Gastric Cancer After Prior Chemotherapy

[PR Newswire] – INDIANAPOLIS, Nov. 5, 2014 /PRNewswire/ — Eli Lilly and Company (NYSE: LLY) announced today that the U.S. Food and Drug Administration (FDA) has approved CYRAMZA ® (ramucirumab) in combination with . . . → Read More: Company Update (NYSE:LLY): Lilly’s CYRAMZA® (ramucirumab) in Combination with Paclitaxel Granted FDA Approval for Advanced Gastric Cancer After Prior Chemotherapy Similar Articles: Company Update (NYSE:LLY): Lilly Declares Fourth-Quarter 2014 Dividend Stock Update (NYSE:LLY): EU Commission clears Eli Lilly, Novartis deal Market Update: Eli Lilly & Company (NYSE:LLY) – Lilly to Participate in Morgan Stanley 2014 Global Healthcare Conference